Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Genitourinary System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm

Cancer Family

Genitourinary System Neoplasm

CI-CAN-00000018Explore in graph →

Non-malignant3,849 active trials61 approved drugs306 evidence items

NCIt: C156482

Overview
Statistics
Survival
Genomics114
Variants & evidence306
Drugs75
Trials17388
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (892)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 726–750 of 892 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement.
· Pathology · 2016 · PMID 27020209 · validated civic_curation pubmed
Whole transcriptome sequencing identifies BCOR internal tandem duplication as a common feature of clear cell sarcoma of the kidney.
· Oncotarget · 2015 · PMID 26516930 · validated civic_curation pubmed
Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.
· Am J Pathol · 2001 · PMID 11438465 · validated civic_curation pubmed
Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization.
· Am J Surg Pathol · 2012 · PMID 22895266 · validated civic_curation pubmed
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
· JCO Precis Oncol · 2023 · PMID 36753688 · validated civic_curation pubmed
Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of kidney.
· J Pathol · 2012 · PMID 22294382 · validated civic_curation pubmed
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors.

Showing 726–750 of 892 publications

← Previous
1
…
29
30
31
…
36
Next →

· Clin Cancer Res · 2021 · PMID 34074656 · validated civic_curation pubmed

Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations.

· J Clin Oncol · 2025 · PMID 39413348 · validated civic_curation pubmed

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.

· Onco Targets Ther · 2015 · PMID 26261420 · validated civic_curation pubmed

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.

· Br J Clin Pharmacol · 2015 · PMID 26033044 · validated civic_curation pubmed

Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.

· Oncotarget · 2015 · PMID 26311741 · validated civic_curation pubmed

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

· Bone Marrow Transplant · 2010 · PMID 19648970 · validated civic_curation pubmed

Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer.

· Tumour Biol · 2016 · PMID 26838030 · validated civic_curation pubmed

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

· Gynecol Oncol · 2010 · PMID 19840887 · validated civic_curation pubmed

TP53 polymorphism, HPV infection, and risk of cervical cancer.

· Cancer Epidemiol Biomarkers Prev · 2001 · PMID 11535556 · validated civic_curation pubmed

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

· Clin Cancer Res · 2013 · PMID 23881929 · validated civic_curation pubmed

A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations.

· Clin Cancer Res · 2020 · PMID 32636318 · validated civic_curation pubmed

Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.

· Mod Pathol · 2019 · PMID 30980040 · validated civic_curation pubmed

SMARCB1/INI1 inactivation in renal medullary carcinoma.

· Histopathology · 2012 · PMID 22686875 · validated civic_curation pubmed

Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.

· Clin Genitourin Cancer · 2017 · PMID 28558987 · validated civic_curation pubmed

Congenital mesoblastic nephroma is characterised by kinase mutations including EGFR internal tandem duplications, the ETV6-NTRK3 fusion, and the rare KLHL7-BRAF fusion.

· Histopathology · 2020 · PMID 32590884 · validated civic_curation pubmed

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

· Nature · 2018 · PMID 29420467 · validated civic_curation pubmed

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.

· Int J Gynaecol Obstet · 2008 · PMID 18555254 · validated civic_curation pubmed

A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.

· Oncol Lett · 2013 · PMID 24137399 · validated civic_curation pubmed

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

· J Clin Oncol · 2015 · PMID 26324360 · validated civic_curation pubmed